11,934 Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART) Purchased by Headlands Technologies LLC

Headlands Technologies LLC acquired a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 11,934 shares of the life sciences company’s stock, valued at approximately $271,000.

A number of other large investors have also recently made changes to their positions in IART. Norges Bank purchased a new stake in Integra LifeSciences during the fourth quarter valued at approximately $8,967,000. Systematic Financial Management LP lifted its stake in Integra LifeSciences by 53.9% in the 3rd quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company’s stock worth $11,115,000 after purchasing an additional 214,272 shares in the last quarter. Access Investment Management LLC bought a new position in Integra LifeSciences during the fourth quarter valued at approximately $4,416,000. Cannell & Spears LLC purchased a new position in Integra LifeSciences during the 4th quarter valued at approximately $3,555,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Integra LifeSciences by 15.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company’s stock worth $17,158,000 after acquiring an additional 125,620 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences currently has an average rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Stock Down 2.4 %

Shares of IART opened at $19.57 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $34.79. The company has a market cap of $1.51 billion, a PE ratio of -217.42, a P/E/G ratio of 0.73 and a beta of 1.24. The business has a fifty day moving average of $23.37 and a 200 day moving average of $22.27.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same period in the previous year, the company earned $0.89 EPS. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. On average, sell-side analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.